Filter by: patients
Home > Community Treatment Reports and Side Effects > Eplerenone Treatment Report
What is Eplerenone?

eplerenone is a selective aldosterone blocker used in treatment of hypertension (may be used alone or in combination with other antihypertensive agents); treatment of CHF following acute MI.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Other 1 0
General health 1 0
Cardiomyopathy 1 1 Efficacy_cant_tell
CHF (Congestive heart failure) 1 0

See all 6 patients currently taking Eplerenone

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 1
Moderate
 0
Mild
 0
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Eplerenone

Dizziness 1

Reported Dosages

  25 mg daily 47.5 mg daily 50 mg daily
  4 Number of Patients: 4 1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Eplerenone (multiple reasons could be selected)
Reason # Patients Percentage of patients
Expense 1   Expense: 100%

See all 1 patient who’ve stopped taking Eplerenone

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Eplerenone

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Eplerenone

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Eplerenone

Always
 0 0%
Usually
 1 100%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Eplerenone

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Eplerenone

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 1 100%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 28, 2012.